FIELD: biotechnology; medicine.
SUBSTANCE: invention claimed is a derivative of a polypeptide acylated at a lysine amino acid residue selected from the group consisting of insulin, glucagon-like peptide-1, parathyroid hormone, and combinations thereof. Experimental results show that said polypeptide derivative has a significantly increased half-life while retaining its biological activity.
EFFECT: invention can be used in treatment of osteoporosis, diabetes and hyperglycemia.
10 cl, 3 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
AMINOACIL-tRNA SYNTHASE FOR EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVE INTO PROTEIN | 2020 |
|
RU2799794C2 |
HYBRID PROTEIN CONTAINING FRAGMENTS OF FLUORESCENT PROTEINS AND ITS APPLICATION | 2020 |
|
RU2801248C2 |
AMINOACIL-tRNA SYNTHASE, EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVES | 2020 |
|
RU2790662C1 |
HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE THEREOF | 2019 |
|
RU2839688C2 |
PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
METHOD FOR PRODUCTION OF ACTIVE FORM OF LONG-ACTING INSULIN ANALOGUE DERIVATIVE, USING CLOSTRIPAIN | 2019 |
|
RU2781307C2 |
METHOD OF GLP-1 MOLECULES INTRODUCTION | 2003 |
|
RU2332229C2 |
PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
Authors
Dates
2023-03-21—Published
2020-05-08—Filed